The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer

Autor: Andrew Henderson, Laura A. Skelly, Marcus Asokendaran, Nat Lenzo, Danielle Meyrick
Rok vydání: 2017
Předmět:
Adult
Male
Biochemical recurrence
Oncology
medicine.medical_specialty
Gallium Radioisotopes
urologic and male genital diseases
030218 nuclear medicine & medical imaging
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Positron Emission Tomography Computed Tomography
Internal medicine
Image Processing
Computer-Assisted
Carcinoma
medicine
Glutamate carboxypeptidase II
Humans
Radiology
Nuclear Medicine and imaging
Edetic Acid
Gallium Isotopes
Aged
Neoplasm Staging
Retrospective Studies
Aged
80 and over
PET-CT
medicine.diagnostic_test
business.industry
Prostatic Neoplasms
Retrospective cohort study
General Medicine
Middle Aged
Prostate-Specific Antigen
medicine.disease
Prostate-specific antigen
Bone scintigraphy
030220 oncology & carcinogenesis
Radiology
business
Oligopeptides
Zdroj: Nuclear Medicine Communications. 38:956-963
ISSN: 0143-3636
DOI: 10.1097/mnm.0000000000000738
Popis: This retrospective study aimed to evaluate the role of Ga-PSMA-IT PET/CT in the primary staging of newly diagnosed prostate cancer (PCa), with a focus on the detection of metastatic nodal disease. Correlation of the rate of detection of metastatic disease by Ga-PSMA-IT PET/CT with the Gleason score (GS) and serum prostate-specific antigen (PSA) was performed to determine the GS and PSA criteria defining patients who would benefit from Ga-PSMA-IT PET/CT imaging for staging, risk stratification and therapy optimization.Patient data and images from 70 patients with a recent diagnosis of prostate cancer who had undergone Ga-PSMA-IT PET/CT were analysed retrospectively. Data and images were analysed for the rate of detection of primary and metastatic PCa, and correlation with PSA and GS.The rate of detection of primary tumour by Ga-PSMA-IT for patients with serum PSA less than 5 ng/ml was 73%. The corresponding rate was 90% for patients with PSA 5-10 ng/ml and 97% for patients with PSA more than 10 ng/ml. Metastatic PCa and/or infiltrative disease was detected in 24/70 study patients in total: 1/11 patients with PSA less than 5 ng/ml and 23/59 patients with serum PSA at least 5 ng/ml. The rate of detection of metastatic PCa was greater in patients with GS 9 or more (48%) relative to those with GS 8 (32%) or GS ≤7 (18%).A role for Ga-PSMA-IT PET/CT in primary PCa staging of high-grade disease (GS 8 or more and PSA10 ng/ml) has been shown. There was a low rate of detection of PSMA-avid metastases in low-grade disease (GS 7 or less and PSA5 ng/ml), suggesting that there is a limited role for this modality in such cases.
Databáze: OpenAIRE
Externí odkaz: